AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) announce a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease (PD), and mood disorders. The acquisition complements AbbVie’s neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across psychiatric and neurological disorders where significant unmet needs remain for patients. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion.

Read the full article: AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline //

Source: https://www.prnewswire.com/news-releases/abbvie-to-acquire-cerevel-therapeutics-in-transformative-transaction-to-strengthen-neuroscience-pipeline-302008134.html

Leave a Comment

Your email address will not be published.

Scroll to Top